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Introduction
Diabetes mellitus and metabolic syndrome (MetS) are major risk factors of vascular calcification (1) . Patients with diabetes have more extensive coronary artery disease, and atherosclerotic plaque morphology in diabetic patients may be predisposed to rupture and thrombosis (2) . Among patients with acute coronary syndromes, patients with co-morbidity diabetes or MetS have a greater lesion length, plaque burden, necrotic core, and calcium content among nonculprit lesions (3). Moreover, higher incidence and progression of coronary artery calcium have also been demonstrated in subjects with MetS or diabetes (4) . However, the underlying mechanism is poorly understood.
Extracellular pyrophosphate and alkaline phosphatase have been identified as key molecules in vascular calcification (1) . Pyrophosphate is a potent inhibitor of tissue mineralization and vascular calcification (5). Pyrophosphate is produced by an enzyme, ectonucleotide pyrophosphatasephosphodiesterease 1 (NPP1), which is located in the cell membrane. It is then transported across the cell membrane to the extracellular matrix by the progressive ankylosis protein (ANK). Bone-specific alkaline phosphatase (BAP) hydrolyzes pyrophosphate and so promotes tissue mineralization (6-7). Knockout mice deficient in NPP1 and ANK have increased aortic calcification (5) and medial calcification (8), respectively. On the other hand, blocking the hydrolyzing action of BAP ameliorated the calcification in vascular smooth muscle cells from NPP1-and ANK-deficient mice (7). Thus, alkaline phosphatase has a critical role in calcification, and it has been extensively used as a marker of calcification (6-7) and exploited as therapeutic target of vascular calcification (7, 9). Previous studies also showed that serum alkaline phosphatase is a predictor of mortality (10-11) and cardiovascular events (11).
A number of studies have investigated the association between serum alkaline phosphatase and diabetes/MetS owing to its role as a hepatobiliary marker. However, serum alkaline phosphatase consists of several alkaline phosphatase isoforms from various tissues, such as liver, bone, and kidney, with a large proportion are derived from liver and bone. Previous studies showed that BAP reflects mineral metabolism with a higher sensitivity and specificity than total alkaline phosphatase (12). Therefore in the current study, we aimed to evaluate the relationship between glucose metabolism, metabolic syndrome, alkaline phosphatase, and BAP in a large nationally-representative population.
Materials and Methods
The current study utilized data from National Health and Nutrition Examination Survey (NHANES) 1999-2004 (13). The NHANES included a stratified multistage probability sample which represented the civilian non-institutionalized U.S. population. Selection was based on counties, blocks, households, and individuals within households. It also included non-Hispanic blacks and Mexican-Americans to provide an adequate estimate of these ethic groups. Participants were required to sign a consent form before their participation, and ethical approval was obtained from the Human Subjects Committee of the U.S. Department of Health and Human Services.
Our analysis included non-pregnant participants aged 20 or above whose BAP and fasting glucose levels were available (n=5,057). We excluded participants with missing data in the multivariable models or without weight in the complex sampling model (n=757) and participants with diabetes (n=527, defined as a plasma glucose level ≥126 mg/dl [7.0 mmol/L] after fasting for a minimum of 8 hours, a glycohemoglobin (HbA1C) value ≥6.5%, self-reported diabetes or self-reported current use of oral hypoglycemic medication or insulin). After exclusion, 3,773 participants were included in the analysis.
BAP and total alkaline phosphatase
Serum BAP was measured using the Hybritech Tandem-MP ostase immunoenzymetric assay (1999) (2000) (2001) (2003) (2004) 
Indices of glucose metabolism
Serum insulin, plasma glucose, and HbA1C were measured at the Diabetes Diagnostic Laboratory, University of Missouri-Columbia. Plasma glucose and serum insulin were measured from fasting blood samples using hexokinase enzymatic method and radioimmunoassay, respectively. HbA1C was measured using Primus CLC330 and Primus CLC 385 analyzers (Primus Corporation, Kansas City, MO). The updated homeostasis model assessment (HOMA2) is more accurate than the original HOMA1, therefore Homeostasis model assessment calculator (14) was used to calculate the HOMA2 beta cell function (%B), insulin sensitivity (%S), and hepatic insulin resistance (IR).
Components of MetS
Lipids (total cholesterol, HDL-cholesterol, triglycerides) were measured enzymatically using Hitachi 704 Analyzer at the lipoprotein analytical laboratory, Johns Hopkins University School of Medicine. Seated systolic and diastolic blood pressures (mm/Hg) were measured using a mercury sphygmomanometer according to the American Heart Association and Seventh Joint National Committee recommendations. Mean arterial pressure (MAP, mm/Hg) was calculated as 2/3 diastolic blood pressure + 1/3 systolic blood pressure.
Independent variables
Age (years), gender (male/female), race/ethnicity (Hispanics, non-Hispanic white, non-Hispanic Black, others), smoking status (current/ former/ non-smokers), alcohol use (drinkers/ non-drinkers), level of education (< high-school, high-school, > high-school), and physical activity (active/ sedentary) were assessed using a questionnaire. We used same definition for never, current and former smokers that is used in the National Health Interview Surveys (NHIS) conducted by Center for Disease Control. Individuals who had not smoked more than 100 cigarettes in their lifetime were considered non-smokers; those who had smoked more than 100 cigarettes in their lifetime were considered former smokers if they answered negatively to the question "Do you smoke now?" and current smokers if they 
Statistical analyses
Glycemic traits and components of MetS were analyzed as continuous and quartile variables. Multivariable linear regression was used to evaluate the association when glycemic traits and components of MetS were modeled as continuous variables. Table 1 shows the sex-stratified characteristics of the 3,773 NHANES 1999 3,773 NHANES -2004 participants who were free from diabetes. Women were older, more likely to be non-Hispanic white, non-smokers., non-active drinkers and had lower physical activity. They had higher HDL-cholesterol levels, CRP, HOMA2-IS, and HOMA2-B.
Results
Conversely they had lower waist circumference, BAP, total alkaline phosphatase, triglyceride levels, MAP, ALT, AST, GGT, HbA1C, fasting glucose levels, insulin concentrations, and HOMA2-IR. Table 2 shows the association between glycemic traits and alkaline phosphatase. After Table 1) . Table 3 shows the association between components of MetS and alkaline phosphatase.
MAP and HDL-cholesterol showed significant association with BAP, while waist circumference and triglycerides showed a trend toward significant association with BAP (0.05 < P < 0.1). On the other hand, MAP and HDL-cholesterol showed significant association with tissue non-specific alkaline phosphatase, while no association was observed with waist circumference and triglycerides. Similar results
were obtained when components of MetS were categorized as quartiles (Supplementary Table 2 ). 
Discussions
The associations and inter-relationships between insulin resistance, components of MetS, and BAP were unraveled in the current study of the US-population using structural equation modeling in addition to multivariable linear regression. Although tissue non-specific alkaline phosphatase is known to correlate with insulin resistance and metabolic syndrome owing to its role as a hepatobiliary marker, our study clearly shows that both hyperinsulinemia, insulin resistance, and MetS are in fact more strongly associated with BAP.
Our study excluded participants with diabetes allowing us to study the relationship of hyperinsulinemia or insulin resistance with BAP, without the confounding effect of Our study sheds light on the mechanism of elevated BAP. While insulin resistance is known to be a risk factor for vascular calcification, the mechanism is not completely understood. In the current study, we showed that multiple HOMA2 indices and insulin levels are robustly associated with BAP rather than total alkaline phosphatase.
Although total alkaline phosphatase could be elevated due to obesity, insulin resistance, fatty liver, and hepatosteatosis, no significant association was observed between HOMA2-IR and total alkaline phosphatase in the fully adjusted model. This may be explained by the fact that other liver markers included in the model were more specific to liver dysfunction; ALT, AST, and GGT also showed significant associations (P<0.05) with HOMA2-IR in the fully adjusted model. When ALT, AST, and GGT were removed from the fully adjusted model, the association between alkaline phosphatase and HOMA2-IR became significant (P = 0.015). On the other hand, elevated BAP could be due to the presence of fatty liver. However, further adjustment for fatty liver index (15), a validated marker of fatty liver, did not change the association of HOMA2-IR, HOMA2-IS, HOMA2-B, and insulin with BAP ( Table   2 ), suggesting that the association was independent of fatty liver. In addition, our study also showed that BAP is associated with multiple components of MetS, which suggested that hyperinsulinemia, insulin resistance, and MetS could lead to serum BAP elevation. In line with our previous studies (22-23), serum CRP was significantly associated with alkaline phosphatase in the current study, while no association was observed with BAP (P > 0.5; data not shown). These observations further suggested that although total alkaline phosphatase and BAP are strongly correlated, the causes of elevation of total alkaline phosphatase and BAP could be different.
There have only been a few studies of BAP with insulin resistance and MetS. In agreement with a cross-sectional study carried out in 328 type 2 diabetes patients, we also observed no significant association between BAP and fasting plasma glucose and HbA1c (24). In a study of 54 healthy postmenopausal women, there was no correlation between BAP and any components of MetS (25), which could be due to the small sample size.
Serum alkaline phosphatase is routinely measured clinically, while BAP is not.
Therefore, most epidemiological studies examined the association of serum alkaline phosphatase with mortality and cardiovascular diseases. Among 4,115 participants of the Cholesterol And Recurrent Events study, alkaline phosphatase was associated with all-cause mortality. This finding was subsequently replicated using NHANES III data, with significant association being observed between alkaline phosphatase and all-cause and cardiovascular mortality (10). Similar results are observed in patients with maintenance hemodialysis (26) and acute stroke (27). In a retrospective study including 10,743 outpatients, serum alkaline phosphatase was robustly associated with mortality (including cardiovascular mortality) and cardiovascular related hospitalization (28). In addition to mortality, serum alkaline phosphatase has been reported to be associated with multiple cardiovascular diseases, such as stroke incidence (29), coronary artery calcification score (30), myocardial infarction, stent thrombosis, major adverse cardiac event, and coronary calcification (11). Our earlier study also showed that elevated alkaline phosphatase is associated with peripheral arterial disease (31). A few studies examined the role of BAP in mortality and cardiovascular diseases. In 130 osteoporotic patients, serum BAP was significantly higher in those with vascular calcification than those without (32). In a prospective study carried out in 800 dialysis patients, serum BAP was robustly associated with cardiovascular and non-cardiovascular mortality, and the effect size was much stronger than that of serum total alkaline phosphatase (33). Altogether, these studies suggested that alkaline phosphatase is an important predictor of mortality and cardiovascular events, while our current study provided evidence that BAP may be the link between insulin resistance and vascular calcification, cardiovascular diseases, or even mortality. Future studies on clinical outcomes should measure BAP in addition to total alkaline phosphatase (11).
BAP is known as a bone formation marker. Our previous study showed that genetic variation in ALPL gene was associated with hip geometry and bone mineral density in 1,513 Framingham Offspring Cohort participants (34). Therefore the associations observed in the current study could reflect difference in bone turnover. We then further adjusted for another bone turnover marker, urinary N-terminal telopeptides, in the logistic regression model ( Table 2 ). Further adjustment for urinary N-terminal telopeptides attenuated the estimates but the associations remained statistically significant. These findings suggest that at least part of the association between glycemic traits and BAP is independent of bone turnover. Similarly, BAP may also be associated with growth. We then performed sensitivity analysis by excluding participants aged <25, and the results were essentially similar to the results before the exclusion (Supplementary Table 3 ). Future study is required to confirm our findings.
The association of MetS with osteoporosis is controversial, with MetS was reported to be associated with higher BMD (35) and lower BMD (36). In previous study, blood pressure was shown to be negatively associated with bone mineral density (36).
However, blood pressure was found to be positively associated with BAP in the current study. It should also be noted that, although BAP is mainly expressed in osteoblast, it is also expressed in other cells, such as B-cell (37) and vascular smooth muscle cells (38). Therefore, serum BAP could also be contributed by other cells, although it is expected to be contributed predominantly by osteoblasts.
Population studies have shown that diabetes is preventable or even reversible.
Therefore, identification of biomarkers may have the potential for early diagnosis of insulin resistance and hence prevention of diabetes (39-40). In this study, we showed that serum BAP concentration is associated with several metabolic traits, therefore BAP could potential be used as a biomarker. Future studies are required to examine whether addition of BAP as a predictive biomarker could enhance the performance of existing prevention strategies such as increased physical activity, healthy diet, and early treatment of hyperglycemia (39-40).
Our study has several strengths. The study population is large, multiethnic, nationally-representative, and well-characterized with data on multiple risk factors and confounders. The findings were shown to be robust in multiple statistical tests.
Nevertheless, there are limitations. First, cross-sectional data cannot prove causality.
Second, although the model in the current study showed a good fit in SEM, this may not be the only plausible model since the mechanisms underlying metabolic risk factors is complex. Future studies incorporating evidence from laboratory and human studies are required to investigate the mechanism in detail. Third, HOMA2 indices are only surrogate markers, for example, HOMA2-IR is a surrogate marker of hepatic insulin resistance; and these indices are strongly correlated with insulin levels. It is unclear whether insulin resistance, insulin levels, or both leads to increased BAP.
Future studies using euglycemic hyperinsulinemic and hyperglycemic clamp techniques are required to confirm our findings. Fourth, as aforementioned, the regulation of BAP is complex, therefore the results should be interpreted with caution.
In conclusion, our study provides a possible mechanism for the increased vascular calcification in subjects with increased insulin resistance such as MetS or type 2 diabetes. Future studies are required to examine whether improving insulin resistance and MetS could reduce the expression of BAP and the risk of vascular calcification and cardiovascular disease.
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